Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
Evaluation of the efficacy and safety of different adjuvant intensification regimens in early-stage BRCA1/2 mutant triple-negative breast cancer.
Breast Carcinoma|BRCA Mutation|Adjuvant Drug Therapy
OTHER: no intervention
iDFS%, 3 years
DRFS%, 3 years|OS%, 3 years
Evaluation of the efficacy and safety of different adjuvant intensification regimens in early-stage BRCA1/2 mutant triple-negative breast cancer.